Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fallopian Tube Cancer: early-phase trial registry
27 of 93 indexed Fallopian Tube Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #145 of 28,707 conditions by registered trial count.
93 US clinical trials · 27 currently recruiting · #145 of 28,707 conditions by registered trial count
Fallopian Tube Cancer: 93 US clinical trials tracked, 27 recruiting.
Fallopian Tube Cancer is the subject of 93 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition fallopian-tube-cancer
OPEN 27 | RECR 29% | LATE 9 | EARLY 74 | RANK #145 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Nonalcoholic Steatohepatitis (29% recruiting · 31 trials)
Fallopian Tube Cancer lists 27 open slots (29% of 93 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fallopian Tube Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fallopian Tube Cancer is recruiting below its size-band peers.
27 of 93 indexed trials (29%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Fallopian Tube Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 9 of 93 trials (9.7%). 60 distinct sponsors appear on at least one study for this condition label.
-
Typical Fallopian Tube Cancer enrolment sits around 60 participants.
Median target enrolment is 60 among the 86 trials that report a genuine target (sentinel values excluded). 49 of those (57%) plan for fewer than 100 participants.
-
Fallopian Tube Cancer research is mostly interventional.
89 interventional and 4 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
93 total, page 1 of 2
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme
NCT06824467
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT05579366
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
NCT04590326
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie
NCT05445778
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06915025
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics
NCT05867251
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
NCT07024784
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT06906341
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics
NCT06690775
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
NCT05281471
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
NCT04516447
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
NCT06890338
Using Aspirin to Improve Immunological Features of Ovarian Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT05080946
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
M.D. Anderson Cancer Center
NCT05287451
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
NCT06469281
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT06290193
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
NCT05887609
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
NCT06856499
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Memorial Sloan Kettering Cancer Center
NCT05429970
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
NCT05071937
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT06342986
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT05739981
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT04701645
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06617923
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Merck Sharp & Dohme
NCT03740165
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
pharmaand
NCT03522246
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Depression Treatment and Screening in Ovarian Cancer Patients
M.D. Anderson Cancer Center
NCT00515372
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT05527184
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Imunon
NCT03393884
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
NCT05456685
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
A Study of Sovilnesib in Subjects With Ovarian Cancer
Volastra Therapeutics
NCT06084416
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
NCT06483997
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
NCT02873962
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
OncoC4
NCT05446298
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
NCT02571725
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Brown University
NCT03355976
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
NCT02884648
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Mercy Medical Center
NCT02124421
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Beth Israel Deaconess Medical Center
NCT00799110
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT04204811
Nudge to Gynecologic Oncology
Abramson Cancer Center at Penn Medicine
NCT06451263
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
University of Oklahoma
NCT03771651
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
NCT03038100
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 35 |
| Phase 3 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Fallopian Tube Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fallopian Tube Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fallopian Tube Cancer page
93 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Fallopian Tube Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Fallopian Tube Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fallopian Tube Cancer condition card totals 93 registered trials; most-linked intervention Bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.